Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.

Purpose: Oral anticoagulants effectively prevent stroke/systemic embolism among patients with non-valvular atrial fibrillation but remain under-prescribed. This study evaluated temporal trends in oral anticoagulant use, the incidence of stroke/systemic embolism and major bleeding, and economic outcomes among elderly patients with non-valvular atrial fibrillation and CHA₂DS₂–VASc scores ≥ 2. Methods: Retrospective analyses were conducted on Medicare claims data from January 1, 2012 through December 31, 2017. Non-valvular atrial fibrillation patients aged ≥ 65 years with CHA₂DS₂–VASc scores ≥ 2 were stratified by calendar year (2013–2016) of care to create calendar-year cohorts. Patient characteristics were evaluated across all cohorts during the baseline period (12 months before diagnosis). Treatment patterns and clinical and economic outcomes were evaluated during the follow-up period (from diagnosis through 12 months). Results: Baseline patient characteristics remained generally similar between 2013 and 2016. Although lack of oral anticoagulant prescriptions among eligible patients remained relatively high, utilization did increase progressively (53–58%). Among treated patients, there was a progressive decrease in warfarin use (79–52%) and a progressive increase in overall direct oral anticoagulant use (21–48%). There were progressive decreases in the incidence of stroke/systemic embolism 1.9–1.4 events per 100 person years) and major bleeding (4.6–3.3 events per 100 person years) as well as all-cause costs between 2013 and 2016. Conclusions: The proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs. [ABSTRACT FROM AUTHOR]